These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36858163)

  • 21. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity.
    Salem ML; Kadima AN; Cole DJ; Gillanders WE
    J Immunother; 2005; 28(3):220-8. PubMed ID: 15838378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
    Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
    J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Nanovaccine Based on Adjuvant Peptide FK-13 and l-Phenylalanine Poly(ester amide) Enhances CD8
    Xie C; You X; Zhang H; Li J; Wang L; Liu Y; Wang Z; Yao R; Tong T; Li M; Wang X; Cui L; Zhang H; Guo H; Li C; Wu J; Xia X
    Adv Sci (Weinh); 2023 Jul; 10(20):e2300418. PubMed ID: 37162249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
    Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
    PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy.
    Song H; Su Q; Nie Y; Zhang C; Huang P; Shi S; Liu Q; Wang W
    Acta Biomater; 2023 Mar; 158():535-546. PubMed ID: 36632876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orchestrated Codelivery of Peptide Antigen and Adjuvant to Antigen-Presenting Cells by Using an Engineered Chimeric Peptide Enhances Antitumor T-Cell Immunity.
    Pan H; Yu S; Zhuang H; Yang H; Jiang J; Yang H; Ren S; Luo G; Yu X; Chen S; Lin Y; Sheng R; Zhang S; Yuan Q; Huang C; Zhang T; Li T; Ge S; Zhang J; Xia N
    Cancer Immunol Res; 2024 Jul; 12(7):905-920. PubMed ID: 38631019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.
    Heidegger S; Kreppel D; Bscheider M; Stritzke F; Nedelko T; Wintges A; Bek S; Fischer JC; Graalmann T; Kalinke U; Bassermann F; Haas T; Poeck H
    EBioMedicine; 2019 Mar; 41():146-155. PubMed ID: 30852164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
    Ishihara J; Ishihara A; Potin L; Hosseinchi P; Fukunaga K; Damo M; Gajewski TF; Swartz MA; Hubbell JA
    Mol Cancer Ther; 2018 Nov; 17(11):2399-2411. PubMed ID: 30097487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
    Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
    J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
    Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
    Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incorporation of the Tat cell-penetrating peptide into nanofibers improves the respective antitumor immune response.
    Mohammadi M; Dehghani P; Mohseninia A; Roozbehani M; Hemphill A; Hesamizadeh K
    J Cell Physiol; 2021 Feb; 236(2):1401-1417. PubMed ID: 32686113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
    Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
    BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination.
    Fromm G; de Silva S; Giffin L; Xu X; Rose J; Schreiber TH
    Cancer Immunol Res; 2016 Sep; 4(9):766-78. PubMed ID: 27364122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
    Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
    Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses.
    Taylor D; Meyer CT; Graves D; Sen R; Fu J; Tran E; Mirza B; Rodriguez G; Lang C; Feng H; Quaranta V; Wilson JT; Kim YJ; Korrer MJ
    Front Immunol; 2022; 13():936129. PubMed ID: 36059502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).
    Guo L; Overholser J; Darby H; Ede NJ; Kaumaya PTP
    Oncoimmunology; 2022; 11(1):2127691. PubMed ID: 36211807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.